Khan Yousaf, Hussain Rafaqat, Rehman Wajid, Khan Shoaib, Maalik Aneela, Iqbal Tayyiaba, Aziz Tariq, Afridi Muhammad Irfan, Alharbi Metab, Alasmari Abdullah F
Department of Chemistry, COMSATS University Islamabad, Islamabad, Pakistan.
College of Biology, Hunan University Changsha, Hunan, China.
Future Med Chem. 2024 Dec;16(24):2627-2636. doi: 10.1080/17568919.2024.2432303. Epub 2024 Dec 8.
Current research work aims to synthesize hybrid compounds with a thiazole-thiazolidinone structure, as potent inhibitors of urease and α-glucosidase enzymes.
These compounds were characterize throughHNMR,CNMR and HREI-MS techniques. These compounds were also evaluated for their potential to inhibit urease and α-glucosidase enzymes for the treatment of urinary tract infections (UTIs) and diabetes treatments. Moreover, molecular docking and ADMET analysis was carried out to confirm biological outcomes.
Compounds-4 (IC = 1.80 ± 0.80 and 3.61 ± 0.59 μM against urease and α-glucosidase, respectively) exhibited significant effectiveness in inhibiting the activity of both enzymes in comparison to the conventional inhibitors thiourea and acarbose. Molecular docking experiments showed that potent compounds exhibited favorable binding orientations in the active sites of urease and α-glucosidase playing a pivotal role in inhibition profile of these compounds. These compounds were also investigated for their drug likeness and were found with desirable attributes for pharmaceutical development. Based on the findings of this research, these compounds have the potential to be developed into effective anti-diabetic and anti-urease treatments in the future.
当前的研究工作旨在合成具有噻唑 - 噻唑烷酮结构的杂化化合物,作为脲酶和α - 葡萄糖苷酶的有效抑制剂。
通过核磁共振氢谱(HNMR)、核磁共振碳谱(CNMR)和高分辨电子轰击电离质谱(HREI - MS)技术对这些化合物进行表征。还评估了这些化合物抑制脲酶和α - 葡萄糖苷酶的潜力,用于治疗尿路感染(UTIs)和糖尿病。此外,进行了分子对接和药物代谢动力学(ADMET)分析以确认生物学结果。
与传统抑制剂硫脲和阿卡波糖相比,化合物 - 4(对脲酶和α - 葡萄糖苷酶的半数抑制浓度(IC)分别为1.80 ± 0.80和3.61 ± 0.59 μM)在抑制这两种酶的活性方面表现出显著效果。分子对接实验表明,强效化合物在脲酶和α - 葡萄糖苷酶的活性位点呈现出有利的结合取向,在这些化合物的抑制作用中起关键作用。还研究了这些化合物的类药性,发现它们具有适合药物开发的特性。基于本研究结果,这些化合物未来有可能被开发成为有效的抗糖尿病和抗脲酶治疗药物。